Posts - Anticoagulant Therapy

Feb 19, 2018 12:38am
From Dave McGlasson, does anyone have a reference on why a geometric mean is used in the INR calculation?  Since we are using 20–30 normal subjects to calculate the mean PT
Jan 11, 2018 7:33pm
We've had a number of discussions comparing point of care PT/INR
Nov 2, 2017 11:41am
George has been communicating with Drs. Elaine Keohane (Rutgers) and Larry Smith (Abbott) about how long to wait after a thrombotic event to collect a specimen for a thrombosis risk profile.
Oct 13, 2017 12:56pm
Another important issue addressed by Dr. James Quesenberry, St. Luke's Laboratory, Sioux City, Iowa. His message: I understood from early on that antithrombin (AT , antithrombin III, ATIII ) deficient patients can't be assayed for unfractionated heparin using the Stago chromogenic anti-Xa heparin assay.  I thought this was an all-or-none issue, only a big deal in congenital severe AT   deficient folks. Today I learned that clients need to locally establish the AT level below which they believe the assay in their hands at their locale to be not accurate.  This seems highly impractical to do, particularly in the non-university small to medium sized community hospital setting.  We were mainly curious as to how other Stago users deal with this.